Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use

Anne Harding  |  March 30, 2016

NEW YORK (Reuters Health)—Medical cannabis reduces chronic pain patients’ opioid use, while improving their quality of life, according to a new survey of Michigan cannabis dispensary patrons.

“They report that when they make that switch they overall feel better,” Dr. Daniel J. Clauw of the University of Michigan, Ann Arbor, told Reuters Health in a telephone interview.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Opioid analgesics are not effective for everyone with chronic pain, carry the risk of addiction, and cause significant mortality and morbidity, Dr. Clauw and his team note in their report, published online on March 19 in the Journal of Pain.

There is some evidence that medical cannabis might be helpful in reducing chronic pain patients’ opioid use, they add, citing a 2014 study that found mortality from opioid overdose fell about 25%, on average, in states that legalized medical cannabis use.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the new study, the researchers surveyed 244 patrons of a medical cannabis dispensary, 185 of whom completed the questionnaire. About two-thirds reported using opioids before starting medical cannabis, while 18% said they continued to use opioids after they began medical cannabis.

On average, patients reported a 64% reduction in their opioid use, and a 45% improvement in their quality of life, after initiating medical cannabis.

The patients also reported a significant drop in the degree to which side effects of medication affected their daily function after starting cannabis, as well as fewer medication side effects.

“They reduced a lot of medications, but the thing that we thought was most impressive both with respect to the magnitude of change and the public health consequences was the fairly dramatic reduction in opioid dose,” Dr. Clauw told Reuters Health.

The study had no external funding. Two coauthors reported disclosures.

Share: 

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:AddictioncannabisChronic painmarijuanaOpioidsPainPain Management

Related Articles

    Cannabis for Pain Relief: An Area Ripe for Research

    September 28, 2023

    Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.

    Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

    March 26, 2018

    As medical and recreational marijuana becomes more accessible, researchers seek creative ways to study the cannabis plant and explore the complexities of the endocannabinoid system in pain relief. Rheumatologists currently face an influx of patients asking if marijuana can help them. Here’s a look at the evolving research on cannabinoids for rheumatologic pain management and how doctors are discussing it with their patients…

    Brandon Crawford / shutterstock.com

    Case Report: Blunt Smoker Denies Tobacco Use, Delaying Diagnosis

    May 12, 2022

    Brandon Crawford / shutterstock.com Cannabis arteritis mirrors thrombo­angiitis obliterans in its clinical and arteriographic presentation, but its relevant exposure is cannabis rather than tobacco.1 Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable. Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, is a peripheral vasoconstrictor.2 This offers mechanistic insight…

    Cannabinoids Show Potential in Pain Management

    February 13, 2020

    About time / shutterstock.com ATLANTA—The potential of cannabis‐based medicines is a hot topic, particularly as pain management therapy for arthritis and other conditions. However, confusion abounds regarding its therapeutic potential, how it can be administered and even the correct terminology to use. David P. Finn, PhD, professor of pharma­cology and therapeutics, and founding co-director of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences